CATALYST PHARMACEUTICALS INC (CPRX) Stock Fundamental Analysis
USA - NASDAQ:CPRX - US14888U1016 - Common Stock
20.9793 USD
+0.43 (+2.09%)
CPRX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making CPRX a very profitable company, without any liquidiy or solvency issues. An interesting combination arises when we look at growth and value: CPRX is growing strongly while it also seems undervalued. These ratings could make CPRX a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
CPRX had positive earnings in the past year.
CPRX had a positive operating cash flow in the past year.
Each year in the past 5 years CPRX has been profitable.
In the past 5 years CPRX always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of CPRX (21.47%) is better than 96.82% of its industry peers.
The Return On Equity of CPRX (24.38%) is better than 96.63% of its industry peers.
CPRX's Return On Invested Capital of 21.45% is amongst the best of the industry. CPRX outperforms 97.75% of its industry peers.
CPRX had an Average Return On Invested Capital over the past 3 years of 20.37%. This is above the industry average of 15.49%.
The 3 year average ROIC (20.37%) for CPRX is below the current ROIC(21.45%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.47% | ||
| ROE | 24.38% | ||
| ROIC | 21.45% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
The Profit Margin of CPRX (37.36%) is better than 97.19% of its industry peers.
In the last couple of years the Profit Margin of CPRX has remained more or less at the same level.
Looking at the Operating Margin, with a value of 43.58%, CPRX belongs to the top of the industry, outperforming 99.06% of the companies in the same industry.
In the last couple of years the Operating Margin of CPRX has grown nicely.
With an excellent Gross Margin value of 85.78%, CPRX belongs to the best of the industry, outperforming 88.39% of the companies in the same industry.
In the last couple of years the Gross Margin of CPRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 43.58% | ||
| PM (TTM) | 37.36% | ||
| GM | 85.78% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
CPRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for CPRX has been increased compared to 1 year ago.
CPRX has more shares outstanding than it did 5 years ago.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CPRX has an Altman-Z score of 15.79. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
CPRX's Altman-Z score of 15.79 is amongst the best of the industry. CPRX outperforms 88.39% of its industry peers.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.79 |
ROIC/WACC2.29
WACC9.37%
2.3 Liquidity
CPRX has a Current Ratio of 6.71. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.71, CPRX is doing good in the industry, outperforming 67.60% of the companies in the same industry.
CPRX has a Quick Ratio of 6.55. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.55, CPRX is doing good in the industry, outperforming 67.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.71 | ||
| Quick Ratio | 6.55 |
3. Growth
3.1 Past
CPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 205.56%, which is quite impressive.
CPRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 34.29% yearly.
The Revenue has grown by 28.54% in the past year. This is a very strong growth!
CPRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.89% yearly.
EPS 1Y (TTM)205.56%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%24.24%
Revenue 1Y (TTM)28.54%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%19.44%
3.2 Future
The Earnings Per Share is expected to grow by 26.50% on average over the next years. This is a very strong growth
Based on estimates for the next years, CPRX will show a quite strong growth in Revenue. The Revenue will grow by 11.27% on average per year.
EPS Next Y13.37%
EPS Next 2Y15.59%
EPS Next 3Y12.05%
EPS Next 5Y26.5%
Revenue Next Year16.03%
Revenue Next 2Y12.76%
Revenue Next 3Y11.61%
Revenue Next 5Y11.27%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 12.71, the valuation of CPRX can be described as correct.
Based on the Price/Earnings ratio, CPRX is valued cheaply inside the industry as 97.38% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.42. CPRX is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 11.99, which indicates a very decent valuation of CPRX.
97.00% of the companies in the same industry are more expensive than CPRX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of CPRX to the average of the S&P500 Index (22.94), we can say CPRX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.71 | ||
| Fwd PE | 11.99 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CPRX is valued cheaply inside the industry as 97.75% of the companies are valued more expensively.
98.13% of the companies in the same industry are more expensive than CPRX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.35 | ||
| EV/EBITDA | 6.62 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of CPRX may justify a higher PE ratio.
CPRX's earnings are expected to grow with 12.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.95
PEG (5Y)0.37
EPS Next 2Y15.59%
EPS Next 3Y12.05%
5. Dividend
5.1 Amount
No dividends for CPRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CPRX (10/20/2025, 3:11:54 PM)
20.9793
+0.43 (+2.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners85.12%
Inst Owner Change0.1%
Ins Owners5.59%
Ins Owner Change1.17%
Market Cap2.57B
Analysts88.57
Price Target34.68 (65.31%)
Short Float %7.56%
Short Ratio5.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.95%
Min EPS beat(2)4.13%
Max EPS beat(2)29.76%
EPS beat(4)4
Avg EPS beat(4)18.54%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)8
Avg EPS beat(8)15.48%
EPS beat(12)11
Avg EPS beat(12)12.83%
EPS beat(16)12
Avg EPS beat(16)7.88%
Revenue beat(2)2
Avg Revenue beat(2)3.81%
Min Revenue beat(2)2.19%
Max Revenue beat(2)5.44%
Revenue beat(4)4
Avg Revenue beat(4)3.37%
Min Revenue beat(4)2.19%
Max Revenue beat(4)5.44%
Revenue beat(8)7
Avg Revenue beat(8)2.76%
Revenue beat(12)11
Avg Revenue beat(12)3.19%
Revenue beat(16)13
Avg Revenue beat(16)2.7%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.61%
EPS NQ rev (3m)-4.05%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.27%
Revenue NQ rev (1m)0.33%
Revenue NQ rev (3m)-0.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.71 | ||
| Fwd PE | 11.99 | ||
| P/S | 4.6 | ||
| P/FCF | 9.35 | ||
| P/OCF | 9.33 | ||
| P/B | 3 | ||
| P/tB | 3.58 | ||
| EV/EBITDA | 6.62 |
EPS(TTM)1.65
EY7.86%
EPS(NY)1.75
Fwd EY8.34%
FCF(TTM)2.24
FCFY10.7%
OCF(TTM)2.25
OCFY10.71%
SpS4.56
BVpS6.99
TBVpS5.87
PEG (NY)0.95
PEG (5Y)0.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.47% | ||
| ROE | 24.38% | ||
| ROCE | 28.34% | ||
| ROIC | 21.45% | ||
| ROICexc | 89.37% | ||
| ROICexgc | 270.38% | ||
| OM | 43.58% | ||
| PM (TTM) | 37.36% | ||
| GM | 85.78% | ||
| FCFM | 49.19% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexcg growth 3Y8.72%
ROICexcg growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.99% | ||
| Cap/Sales | 0.07% | ||
| Interest Coverage | 165.59 | ||
| Cash Conversion | 97.81% | ||
| Profit Quality | 131.65% | ||
| Current Ratio | 6.71 | ||
| Quick Ratio | 6.55 | ||
| Altman-Z | 15.79 |
F-Score6
WACC9.37%
ROIC/WACC2.29
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)205.56%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%24.24%
EPS Next Y13.37%
EPS Next 2Y15.59%
EPS Next 3Y12.05%
EPS Next 5Y26.5%
Revenue 1Y (TTM)28.54%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%19.44%
Revenue Next Year16.03%
Revenue Next 2Y12.76%
Revenue Next 3Y11.61%
Revenue Next 5Y11.27%
EBIT growth 1Y183.49%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year63.54%
EBIT Next 3Y23.99%
EBIT Next 5YN/A
FCF growth 1Y121.55%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y121.67%
OCF growth 3Y58.35%
OCF growth 5Y47.28%